BlossomHill Therapeutics, Inc.

SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced an upcoming poster presentation highlighting preclinical and clinical data for BH-30236 at the 68th American Society of Hematology (ASH) Annual Meeting, being held December 12-15, 2026, in New Orleans, Louisiana.…

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced its participation in Guggenheim's 3rd Annual Healthcare Innovations Conference being held at the Intercontinental Boston. Management will participate in a fireside chat on Tuesday, November 10, 2026, at 3:00 pm E…

BlossomHill Therapeutics achieved major de-risking milestones within 80 days post-IPO, including Fast Track and a key companion diagnostic partnership. I see the C797S lung cancer indication as a strategic beachhead, not a niche, leveraging a clear biomarker and no approved oral targeted therapies. BLSM's $220M pro forma cash supports seven to eight quarters of runway, funding Phase 2 initiation but likely requiring further equity for commercialization.

SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced a collaboration with Foundation Medicine, Inc. to develop a companion diagnostic assay (CDx) for the EGFR C797S resistance mutation. The collaboration will leverage the ongoing Phase 1/2 SOLARA clinical trial eva…

BlossomHill Therapeutics, Inc. (NASDAQ: BLSM - Get Free Report)'s share price traded down 4.9% on Wednesday. The stock traded as low as $20.33 and last traded at $20.33. Approximately 22,349 shares changed hands during mid-day trading, a decline of 90% from the average daily volume of 221,659 shares. The stock had previously closed at $21.37. Analysts

BlossomHill Therapeutics, Inc. (NASDAQ: BLSM - Get Free Report) shares gapped up before the market opened on Tuesday. The stock had previously closed at $19.75, but opened at $21.17. BlossomHill Therapeutics shares last traded at $21.27, with a volume of 10,184 shares. Analysts Set New Price Targets A number of research analysts have recently weighed in

Preclinical data demonstrate prolonged KRAS target engagement and potent antitumor activity across multiple KRAS-mutant cancer models, supporting the continued advancement of BH-501284 toward an IND submission in Q1 2027

Strengthened balance sheet with successful completion of upsized $168.3 million initial public offering Announced FDA Fast Track designation for BH-30643 for the treatment of advanced EGFR C797S-positive NSCLC SAN DIEGO, Sept. 18, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced f…

45% objective response rate and 88% disease control rate observed in patients with EGFR C797S-positive resistance to prior EGFR inhibitors, with or without concurrent T790M, a difficult-to-treat population with no approved targeted therapies BH-30643 demonstrated a favorable safety profile with low rates of dose reduction or discontinuation due to treatment-related adverse events Presentation follows receipt of FDA Fast Track designation for BH-30643 for the treatment of advanced or metastatic E…

BlossomHill Therapeutics' (NASDAQ: BLSM - Get Free Report) quiet period will end on Wednesday, September 16th. BlossomHill Therapeutics had issued 9,375,000 shares in its public offering on August 7th. The total size of the offering was $150,000,000 based on an initial share price of $16.00. During BlossomHill Therapeutics' quiet period, insiders and any underwriters involved in

SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced that it will present at the 8th Annual RAS-Targeted Drug Development Summit and the H.C. Wainwright 28th Annual Global Investment Conference.

Data to be presented in a mini-oral session will describe anti-tumor activity of BH-30643 in patients with secondary EGFR resistance mutations such as EGFR C797S  BH-30643 was recently granted Fast Track designation by the FDA for the treatment of C797S-positive resistance in EGFR-mutant NSCLC, a setting where no oral targeted therapies are approved SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an …

SAN DIEGO, Aug. 18, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BH-30643 for the treatment of adult patients with advanced or metastatic epidermal growth factor receptor (EGFR) C797S-positi…

BlossomHill Therapeutics, Inc. (NASDAQ: BLSM - Get Free Report) Director Bihua Chen acquired 312,500 shares of the business's stock in a transaction dated Monday, August 10th. The shares were bought at an average price of $16.00 per share, for a total transaction of $5,000,000.00. Following the acquisition, the director owned 3,614,034 shares of the company's stock,